Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Infinant Health's patented drug candidate is a Bifidobacterium longum subspecies infantis strain, INF108, being developed for the prevention of necrotizing enterocolitis in pre-term infants.
Lead Product(s): INF108
Therapeutic Area: Gastroenterology Product Name: INF108
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024